Multispecialty approach for improving outcomes in juvenile dermatomyositis

References

• Rider LG, Lindsley CB, Miller FW. Juvenile dermatomyositis In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of Pediatric Rheumatology. 7th ed. Philadelphia: Saunders Elsevier; 2016:351–383.
   Google Scholar
• Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24–38. doi:10.1111/joim.1244427028907
   PubMed Web of Science ®Google Scholar
• Miller FW, Cooper RG, Vencovský J, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65(12):3239–3247. doi:10.1002/art.3813723983088
   PubMed Web of Science ®Google Scholar
• Lintner KE, Patwardhan A, Rider LG, et al. Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. Ann Rheum Dis. 2016;75(9):1599–1606. doi:10.1136/annrheumdis-2015-20776226493816
   PubMed Web of Science ®Google Scholar
• Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: latest advances. Best Pract Res Clin Rheumatol. 2017;31(4):535–557. doi:10.1016/j.berh.2017.12.00329773272
   PubMed Web of Science ®Google Scholar
• Simon JP, Marie I, Jouen F, Boyer O, Martinet J. Autoimmune myopathies: where do we stand? Front Immunol. 2016;7:234. doi:10.3389/fimmu.2016.0023427379096
   PubMed Web of Science ®Google Scholar
• Sanner H, Schwartz T, Flatø B, Vistnes M, Christensen G, Sjaastad I. Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage. PLoS One. 2014;9(3):e92171. doi:10.1371/journal.pone.009217124647150
   PubMed Web of Science ®Google Scholar
• Enders FB, Delemarre EM, Kuemmerle-Deschner J, et al. Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity. Ann Rheum Dis. 2015;74(1):315–317. doi:10.1136/annrheumdis-2014-20628725269830
   PubMed Web of Science ®Google Scholar
• Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–340. doi:10.1136/annrheumdis-2016-20924727515057
   PubMed Web of Science ®Google Scholar
• Miyamae T, Sano F, Ozawa R, Imagawa T, Inayama Y, Yokota S. Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis. Pediatr Rheumatol Online J. 2010;8(1):6. doi:10.1186/1546-0096-8-620181085
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Kobayashi I, Mori M, et al. Increased serum B Cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol. 2015;42(12):2412–2418. doi:10.3899/jrheum.14097726472413
   PubMed Web of Science ®Google Scholar
• Tansley SL, Simou S, Shaddick G, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017;84:55–64. doi:10.1016/j.jaut.2017.06.00728663002
   PubMed Web of Science ®Google Scholar
• Rosina S, Varnier GC, Mazzoni M, Lanni S, Malattia C, Ravelli A. Innovative research design to meet the challenges of clinical trials for juvenile dermatomyositis. Curr Rheumatol Rep. 2018;20(5):29. doi:10.1007/s11926-018-0734-429637406
   PubMed Web of Science ®Google Scholar
• Deakin CT, Yasin SA, Simou S, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol. 2016;68(11):2806–2816. doi:10.1002/art.3975327214289
   PubMed Web of Science ®Google Scholar
• Vercoulen Y, Bellutti EF, Meerding J, et al. Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood. PLoS One. 2014;9(8):e105353. doi:10.1371/journal.pone.010535325157414
   PubMed Web of Science ®Google Scholar
• Papadopoulou C, Wedderburn LR. Treatment of juvenile dermatomyositis: an update. Pediatr Drugs. 2017;19(5):423–434. doi:10.1007/s40272-017-0240-6
   Web of Science ®Google Scholar
• Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis. Front Pediatr. 2018;6:284. doi:10.3389/fped.2018.0028430356795
   PubMed Web of Science ®Google Scholar
• Baumann M, Gumpold C, Mueller-Felber W, et al. Pattern of myogenesis and vascular repair in early and advanced lesions of juvenile dermatomyositis. Neuromuscul Disord. 2018;28(12):973–985. doi:10.1016/j.nmd.2018.09.00230389421
   PubMed Web of Science ®Google Scholar
• Varsani H, Charman SC, Li CK, et al. Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Ann Rheum Dis. 2015;74(1):204–210. doi:10.1136/annrheumdis-2013-20339624064003
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138. doi:10.1186/ar460024989778
   PubMed Web of Science ®Google Scholar
• Wakiguchi H, Takei S, Imanaka H, et al. Severe gluteal skin ulcers in an infant with juvenile dermatomyositis. Eur J Dermatol. 2016;26(2):192–193. doi: 10.1684/ejd.2015.270126712099
   PubMed Web of Science ®Google Scholar
• Shimizu M, Ueno K, Ishikawa S, Kasahara Y, Yachie A. Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis. Rheumatology (Oxford). 2014;53(4):766–767. doi:10.1093/rheumatology/ket36024191066
   PubMed Web of Science ®Google Scholar
• Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72. doi:10.1002/acr.2001520191492
   PubMed Web of Science ®Google Scholar
• Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16(12):467. doi:10.1007/s11926-014-0467-y25366934
   PubMed Web of Science ®Google Scholar
• Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo clinic experience with 78 patients, 1996–2009. Arch Dermatol. 2012;148(4):455–462. doi:10.1001/archdermatol.2011.205222184719
   PubMedGoogle Scholar
• Martin N, Krol P, Smith S, et al. Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res (Hoboken). 2012;64(11):1665–1672. doi:10.1002/acr.2175322674907
   PubMed Web of Science ®Google Scholar
• Wakiguchi H, Takei S, Kawano Y. Axillary skin ulcers in infants with juvenile dermatomyositis. Pediatr Neonatol. 2017;58(3):287–288. doi:10.1016/j.pedneo.2016.07.00127733312
   PubMed Web of Science ®Google Scholar
• Barth Z, Schwartz T, Flatø B, et al. The association between nailfold capillary density and pulmonary and cardiac involvement in medium- to long-standing juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2019;71(4):492–497. doi:10.1002/acr.23687
   Web of Science ®Google Scholar
• Mathiesen PR, Buchvald F, Nielsen KG, Herlin T, Friis T, Nielsen S. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. Rheumatology (Oxford). 2014;53(4):644–649. doi:10.1093/rheumatology/ket38024310298
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford). 2015;54(5):784–791. doi:10.1093/rheumatology/keu38525288783
   PubMed Web of Science ®Google Scholar
• Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223–243. doi:10.1097/MD.0b013e31829d08f923877355
   PubMed Web of Science ®Google Scholar
• Dogra S, Suri D, Shah R, Rawat A, Singh S, Sodhi KS. Spontaneous pneumomediastinum: a rare complication of juvenile dermatomyositis. Int J Rheum Dis. 2012;15(5):e131–133. doi:10.1111/apl.2012.15.issue-523083050
   PubMed Web of Science ®Google Scholar
• Prestridge A, Morgan G, Ferguson L, Huang CC, Pachman LM. Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters in children. Arthritis Care Res (Hoboken). 2013;65(9):1424–1431. doi:10.1002/acr.2201423568855
   PubMed Web of Science ®Google Scholar
• Cantez S, Gross GJ, MacLusky I, Feldman BM. Cardiac findings in children with juvenile dermatomyositis at disease presentation. Pediatr Rheumatol Online J. 2017;15(1):54. doi:10.1186/s12969-017-0182-028693511
   PubMed Web of Science ®Google Scholar
• Schwartz T, Sanner H, Gjesdal O, Flatø B, Sjaastad I. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis. 2014;73(10):1805–1810. doi:10.1136/annrheumdis-2014-20531023881732
   PubMed Web of Science ®Google Scholar
• Berntsen KS, Edvardsen E, Hansen BH, Flatø B, Sjaastad I, Sanner H. Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active/inactive disease. Rheumatology (Oxford). 2019;58(3):492–501. doi:10.1093/rheumatology/key342
   Web of Science ®Google Scholar
• Wakiguchi H, Hasegawa S, Hirano R, Kaneyasu H, Wakabayashi-Takahara M, Ohga S. Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels. Pediatr Rheumatol Online J. 2015;13:49. doi:10.1186/s12969-015-0048-226581448
   PubMed Web of Science ®Google Scholar
• Grom AA. Macrophage activation syndrome In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of Pediatric Rheumatology. 7th ed. Philadelphia: Saunders Elsevier; 2016:642–649.
   Google Scholar
• Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol. 2010;32(3):189–191. doi:10.1097/MPH.0b013e3181bf29a220057323
   PubMed Web of Science ®Google Scholar
• Bingham A, Mamyrova G, Rother KI, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008;87(2):70–86. doi:10.1097/MD.0b013e31816bc60418344805
   PubMed Web of Science ®Google Scholar
• Choi RY, Swan RJ, Hersh A, Vitale AT. Retinal manifestations of juvenile dermatomyositis: case report of bilateral diffuse chorioretinopathy with paracentral acute middle maculopathy and review of the literature. Ocul Immunol Inflamm. 2018;26(6):929–933. doi:10.1080/09273948.2017.130542128448730
   PubMed Web of Science ®Google Scholar
• Kountz-Edwards S, Aoki C, Gannon C, Gomez R, Cordova M, Packman W. The family impact of caring for a child with juvenile dermatomyositis. Chron Illness. 2017;13(4):262–274. doi:10.1177/1742395317690034
   Web of Science ®Google Scholar
• Malattia C, Damasio MB, Madeo A, et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis. 2014;73(6):1083–1090. doi:10.1136/annrheumdis-2014-20531023636654
   PubMed Web of Science ®Google Scholar
• Sakurai N, Hino-Shishikura A, Nozawa T, et al. Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. Mod Rheumatol. Epub 2018 Oct 18. doi:10.1080/14397595.2018.1511026
   Web of Science ®Google Scholar
• Abdul-Aziz R, Yu CY, Adler B, et al. Muscle MRI at the time of questionable disease flares in juvenile dermatomyositis (JDM). Pediatr Rheumatol Online J. 2017;15(1):25. doi:10.1186/s12969-017-0154-428403889
   PubMed Web of Science ®Google Scholar
• Habers GE, Van Brussel M, Bhansing KJ, et al. Quantitative muscle ultrasonography in the follow-up of juvenile dermatomyositis. Muscle Nerve. 2015;52(4):540–546. doi:10.1002/mus.2456425557638
   PubMed Web of Science ®Google Scholar
• Shahi V, Wetter DA, Howe BM, Ringler MD, Davis MD. Plain radiography is effective for the detection of calcinosis cutis occurring in association with autoimmune connective tissue disease. Br J Dermatol. 2014;170(5):1073–1079. doi:10.1111/bjd.2014.170.issue-524329416
   PubMed Web of Science ®Google Scholar
• Pouessel G, Deschildre A, Le Bourgeois M, et al. The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol. 2013;48(10):1016–1025. doi:10.1002/ppul.2274223281200
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–678. doi:10.1016/S0140-6736(15)01021-126645190
   PubMed Web of Science ®Google Scholar
• Dagher R, Desjonquères M, Duquesne A, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711–716. doi:10.1007/s00296-010-1653-521152922
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1446–1451. doi:10.1002/acr.2026920521307
   PubMed Web of Science ®Google Scholar
• Deakin CT, Campanilho-Marques R, Simou S, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheumatol. 2018;70(5):785–793. doi:10.1002/art.4041829342499
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–324. doi:10.1002/art.3775423124935
   PubMed Web of Science ®Google Scholar
• Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW. CARRA legacy registry investigators. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J. 2018;16(1):84. doi:10.1186/s12969-018-0299-930594206
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670–1677. doi:10.1136/ard.2007.07797418272672
   PubMed Web of Science ®Google Scholar
• Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019;142(3):e8. doi:10.1093/brain/awz005
   Web of Science ®Google Scholar
• Wakiguchi H, Ohga S. Clinical utility of the liposteroid therapy: potential effects on the macrophage activation. Jpn J Clin Immunol. 2016;39(3):190–196. doi:10.2177/jsci.39.190
   PubMedGoogle Scholar
• Nakagishi Y, Shimizu M, Kasai K, Miyoshi M, Yachie A. Successful therapy of macrophage activation syndrome with dexamethasone palmitate. Mod Rheumatol. 2016;26(4):617–620. doi:10.3109/14397595.2014.90605324754272
   PubMed Web of Science ®Google Scholar
• Shimizu M, Yokoyama T, Tokuhisa Y, et al. Distinct cytokine profile in juvenile systemic lupus erythematosus-associated macrophage activation syndrome. Clin Immunol. 2013;146(2):73–76. doi:10.1016/j.clim.2012.11.00423291246
   PubMed Web of Science ®Google Scholar
• Wakiguchi H. Liposteroid therapy for juvenile and adult dermatomyositis: efficacy and side effects. Ann Transl Med. 2017;5(5):110. doi:10.21037/atm28361075
   PubMed Web of Science ®Google Scholar
• Omori CH, Silva CA, Sallum AM, et al. Exercise training in juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2012;64(8):1186–1194. doi:10.1002/acr.2168422505288
   PubMed Web of Science ®Google Scholar
• Alemo Munters L, Dastmalchi M, Katz A, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther. 2013;15(4):R83. doi:10.1186/ar426323941324
   PubMed Web of Science ®Google Scholar
• Alexanderson H. Physical exercise as a treatment for adult and juvenile myositis. J Intern Med. 2016;280(1):75–96. doi:10.1111/joim.1248126854121
   PubMed Web of Science ®Google Scholar
• Habers GE, Bos GJ, van Royen-Kerkhof A, et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. Rheumatology (Oxford). 2016;55(7):1251–1262. doi:10.1093/rheumatology/kew02627018060
   PubMed Web of Science ®Google Scholar
• Zhu J, Su G, Lai J, et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study. Pediatr Rheumatol Online J. 2018;16(1):72. doi:10.1186/s12969-018-0284-330458860
   PubMed Web of Science ®Google Scholar
• Welborn MC, Gottschalk H, Bindra R. Juvenile dermatomyositis: a case of calcinosis cutis of the elbow and review of the literature. J Pediatr Orthop. 2015;35(5):e43–46. doi:10.1097/BPO.000000000000035825412072
   PubMed Web of Science ®Google Scholar
• Neely J, Long CS, Sturrock H, Kim S; CARRA Registry Investigators. The association of short-term UV radiation exposure and disease severity in juvenile dermatomyositis. Arthritis Care Res (Hoboken) Epub 2019 Feb 4. doi:10.1002/acr.23840
   Google Scholar
• Guissa VR, Pereira RM, Sallum AM, et al. Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy. Clin Exp Rheumatol. 2012;30(4):583–588. doi:none22931582
   PubMed Web of Science ®Google Scholar
• Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J. 2011;30(3):208–211. doi:10.1097/INF.0b013e3181f7ce4420861757
   PubMed Web of Science ®Google Scholar
• Mori M. Pediatric rheumatic diseases: a review regarding the improvement of long-term prognosis and the transition to adults. Immunol Med. 2018;41(1):2–5. doi:10.1080/09114300.2018.145159130938254
   PubMedGoogle Scholar